Cannabidiol treatment in a murine model of systemic lupus erythematosus accelerates proteinuria development

Daphna Katz-Talmor, Shaye Kivity, Miri Blank, Itai Katz, Ori Perry, Alexander Volkov, Iris Barshack, Howard Amital, Yehuda Shoenfeld

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Cannabidiol is a non-psychotropic component of cannabis sativa. Known to induce an immunomodulatory effect, cannabidiol’s therapeutic properties have been explored in a number of autoimmune diseases. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by its varied manifestation and systemic involvement. Objectives: To evaluate the effect of cannabidiol on disease progression in a murine model of SLE. Methods: NZBxW/F 1 mice were treated with either cannabidiol or vehicle by subcutaneous injections. Disease progression was estimated by measurements of proteinuria, histological evaluation of renal disease, levels of anti-dsDNA antibodies, and survival analysis. Results: Mice treated with cannabidiol exhibited rapid progression of glomerular disease with significantly increased proteinuria compared to the control group. Survival analysis revealed a trend (P = 0.058) toward decreased survival among mice treated with cannabidiol. No statistical difference was observed in levels of anti-dsDNA antibodies. Conclusions: Cannabidiol accelerated disease progression in a murine model of SLE. Caution is advised in cannabinoid treatment for SLE patients until further data are collected.

Original languageEnglish
Pages (from-to)741-745
Number of pages5
JournalIsrael Medical Association Journal
Volume20
Issue number12
StatePublished - Dec 2018

Keywords

  • Cannabidiol
  • Cannabinoids
  • Cannabis
  • NZBxW/F1
  • Systemic lupus erythematosus (SLE)

Fingerprint

Dive into the research topics of 'Cannabidiol treatment in a murine model of systemic lupus erythematosus accelerates proteinuria development'. Together they form a unique fingerprint.

Cite this